[1]李锦 王钟海 汪汉.瘦素作为遗传预测的银屑病与心肌梗死之间的潜在中介因素：一项网络孟德尔随机化研究[J].心血管病学进展,2024,(9):853.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.018]
　LI Jin,WANG Zhonghai,WANG Han.Leptin as A Potential Mediator of Genetically Predicted Psoriasis with Myocardial Infarction:A Network Mendelian Randomization Study[J].Advances in Cardiovascular Diseases,2024,(9):853.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.018]
点击复制

瘦素作为遗传预测的银屑病与心肌梗死之间的潜在中介因素：一项网络孟德尔随机化研究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年9期
页码:
853
栏目:
论著
出版日期:
2024-09-25

文章信息/Info

Title:
Leptin as A Potential Mediator of Genetically Predicted Psoriasis with Myocardial Infarction:A Network Mendelian Randomization Study
作者:
李锦1 王钟海2 汪汉1
(1.成都市第三人民医院心内科 成都市心血管病研究所,四川 成都 610031;2.川北医学院附属医院老年科,四川 南充 637100)
Author(s):
LI Jin1; WANG Zhonghai2; WANG Han1
(1.Department of Cardiology,The Third People’s Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu,Chengdu 610031,Sichuan,China; 2.Department of Geriatrics,Affiliated Hospital of North Sichuan Medical College,Nanchong 637100,Sichuan,China) (19YYJC0580) E-mail7972348@qq.com
关键词:
银屑病; 心肌梗死; 瘦素; 孟德尔随机化
Keywords:
Psoriasis; Myocardial infarction; Leptin; Mendelian randomization
DOI:
10.16806/j.cnki.issn.1004-3934.2024.09.018
摘要:
目的 运用网络孟德尔随机化（MR）研究评估遗传预测的银屑病与心肌梗死（MI）之间的因果关系，以及瘦素作为潜在中介因素的作用。方法 这是一项利用全基因组关联分析进行网络MR的研究。网络MR被用于评估银屑病与MI之间的关联，采用中介分析估计瘦素作为遗传预测的银屑病与MI之间的潜在中介因素。结果 本研究表明，遗传预测的银屑病与MI有关联（OR=1.004，95% CI 1.001～1.008， P=0.044），在FinnGen验证数据集中也得到了确认（OR=1.006，95% CI 1.001～1.012， P=0.025），该结果也在汇总的荟萃分析中被证实（OR=1.005，95% CI 1.002～1.008，P＜0.001）。进一步的中介分析表明，遗传预测的银屑病也与瘦素有关（β=0.003，SE=0.001，P=0.047）。此外，瘦素水平每增加一个单位，MI的风险增加13.1%（OR=1.131，95% CI 1.007～1.269， P=0.037）。结论 本研究提供的证据表明银屑病与MI密切相关，可能通过瘦素介导，干预瘦素可能有助于降低银屑病患者MI的发病率。
Abstract:
Objective The Mendelian randomization(MR) study aim ed to assess the causal relationship of genetically predicted psoriasis with myocardial infarction(MI),as well as the role of leptin as a potential mediator. Methods This was a network MR study that utilized genome-wide association study. Network MR was used to evaluate the association between psoriasis and MI,and mediation analysis was used to estimate leptin as a potential mediator for genetically predicted psoriasis with MI. Results This findings indicated that genetically predicted psoriasis was associated with MI( OR=1.004,95% CI 1.001～1.008, P=0.044),which was confirmed in the FinnGen validation dataset(OR=1.006,95% CI 1.001～1.012, P=0.025),as well as in the pooled meta-analysis(OR=1.005,95% CI 1.002～1.008, P＜0.001). Further mediation analysis suggested that genetically predicted psoriasis was also associated with leptin(β=0.003, SE=0.001,P=0.047). Moreover,for every unit increased in leptin levels,the risk of MI increase d by 13.1%(OR=1.131,95% CI 1.007～1.269, P=0.037). Conclusion This study provided evidence that psoriasis was closely associated with MI,which may be mediated by leptin. Intervention with leptin may help to reduce the incidence of MI in patients with psoriasis

参考文献/References:

[1] Griffiths CEM,Armstrong AW,Gudjonsson JE,et al. Psoriasis[J]. Lancet,2021,397(10281):1301-1315.

[2] Li DP,Han YX,He YS,et al. A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040[J]. Autoimmun Rev,2023,22(10):103407.

[3] Cao F,He YS,Wang Y,et al. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019[J]. Autoimmun Rev,2023,22(6):103326.

[4] Kaleta K,Krupa J,Suchy W,et al. Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis:overview and comparison with rheumatoid arthritis[J]. Rheumatol Int,2024 Mar 24.?DOI: 10.1007/s00296-024-05556-x.

[5] Xu T,Zhang YH. Association of psoriasis with stroke and myocardial infarction:meta-analysis of cohort studies[J]. Br J Dermatol,2012,167(6):1345-1350.

[6] Abuabara K,Azfar RS,Shin DB,et al. Cause-specific mortality in patients with severe psoriasis:a population-based cohort study in the U.K[J]. Br J Dermatol,2010,163(3):586-592.

[7] Reed WB,Becker SW,Rohde R,et al. Psoriasis and arthritis. Clinicopathologic study[J]. Arch Dermatol,1961,83:541-548.

[8] Leisner MZ,Lindorff Riis J,Gniadecki R,et al. Psoriasis and risk of myocardial infarction before and during an era with biological therapy:a population-based follow-up study[J]. J Eur Acad Dermatol Venereol,2018,32(12):2185-2190.

[9] Mehta NN,Azfar RS,Shin DB,et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality:cohort study using the General Practice Research Database[J]. Eur Heart J,2010,31(8):1000-1006.

[10] Wakkee M,Herings RMC,Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations:results of a large population-based Dutch cohort[J]. J Invest Dermatol,2010,130(4):962-967.

[11] Nair RP,Duffin KC,Helms C,et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways[J]. Nat Genet,2009,41(2):199-204.

[12] Ghoreschi K,Balato A,Enerb?ck C,et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis[J]. Lancet,2021,397(10275):754-766.

[13] González-Cantero A,Ortega-Quijano D,?lvarez-Díaz N,et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis:a systematic review and meta-analysis of randomized placebo-controlled trials[J]. J Invest Dermatol,2021,141(10):2402-2411.

[14] Joel MG. Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer[J]. J Am Acad Dermatol,2018,79(1):69-70.

[15] Kyriakou A,Patsatsi A,Sotiriadis D,et al. Effects of treatment for psoriasis on circulating levels of leptin,adiponectin and resistin:a systematic review and meta-analysis[J]. Br J Dermatol,2018,179(2):273-281.

[16] Kaur S,Zilmer K,Leping V,et al. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis[J]. J Eur Acad Dermatol Venereol,2011,25(11):1328-1333.

[17] Kyriakou A,Patsatsi A,Sotiriadis D,et al. Serum leptin,resistin,and adiponectin concentrations in psoriasis:a meta-analysis of observational studies[J]. Dermatology,2017,233(5):378-389.

[18] S?derberg S,Ahrén B,Jansson JH,et al. Leptin is associated with increased risk of myocardial infarction[J]. J Intern Med,1999,246(4):409-418.

[19] Robati RM,Partovi-Kia M,Haghighatkhah HR,et al. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis:is psoriasis associated with atherosclerosis?[J]. J Am Acad Dermatol,2014,71(4):642-648.

[20] Romero-Corral A,Sierra-Johnson J,Lopez-Jimenez F,et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population[J]. Nat Clin Pract Cardiovasc Med,2008,5(7):418-425.

[21] Wolk R,Berger P,Lennon RJ,et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis[J]. J Am Coll Cardiol,2004,44(9):1819-1824.

[22] Emdin CA,Khera AV,Kathiresan S. Mendelian randomization[J]. JAMA,2017,318(19):1925-1926.

[23] Burgess S,Daniel RM,Butterworth AS,et al. Network Mendelian randomization:using genetic variants as instrumental variables to investigate mediation in causal pathways[J]. Int J Epidemiol,2015,44(2):484-495.

[24] Skrivankova VW,Richmond RC,Woolf BAR,et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization:the STROBE-MR Statement[J]. JAMA,2021,326(16):1614-1621.

[25] Tsoi LC,Spain SL,Knight J,et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity[J]. Nat Genet,2012,44(12):1341-1348.

[26] Nikpay M,Goel A,Won HH,et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease[J]. Nat Genet,2015,47(10):1121-1130.

[27] Kilpel?inen TO,Carli JF,Skowronski AA,et al. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels[J]. Nat Commun,2016,7:10494.

[28] Choi J,Shen S. Two-sample instrumental-variables regression with potentially weak instruments[J]. Stata J,2019,19(3):581-597.

[29] Xue H,Shen X,Pan W. Causal inference in transcriptome-wide association studies with invalid instruments and GWAS summary data[J]. J Am Stat Assoc,2023,118(543):1525-1537.

[30] Liu Z,Ye T,Sun B,et al. Mendelian randomization mixed-scale treatment effect robust identification and estimation for causal inference[J]. Biometrics,2022,79(3):2208-2219.

[31] Chen L,Yang H,Li H,et al. Insights into modifiable risk factors of cholelithiasis:a Mendelian randomization study[J]. Hepatology,2022,75(4):785-796.

[32] Garshick MS,Ward NL,Krueger JG,et al. Cardiovascular risk in patients with psoriasis:JACC review topic of the week[J]. J Am Coll Cardiol,2021,77(13):1670-1680.

[33] Liu X,Li C,Sun X,et al. Genetically predicted insomnia in relation to 14 cardiovascular conditions and 17 cardiometabolic risk factors:a Mendelian randomization study[J]. J Am Heart Assoc,2021,10(15):e020187.

[34] Gelfand JM,Neimann AL,Shin DB,et al. Risk of myocardial infarction in patients with psoriasis[J]. JAMA,2006,296(14):1735-1741.

[35] Zhang L,Wang Y,Qiu L,et al. Psoriasis and cardiovascular disease risk in European and East Asian populations:evidence from meta-analysis and Mendelian randomization analysis[J]. BMC Med,2022,20(1):421.

[36] Gao N,Kong M,Li X,et al. The association between psoriasis and risk of cardiovascular disease:a Mendelian randomization analysis[J]. Front Immunol,2022,13:918224.

[37] Patrick MT,Li Q,Wasikowski R,et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease[J]. Nat Commun,2022,13(1):6565.

[38] Sierra-Johnson J,Romero-Corral A,Lopez-Jimenez F,et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population[J]. Am J Cardiol,2007,100(2):234-239.

[39] Miller IM,Ellervik C,Yazdanyar S,et al. Meta-analysis of psoriasis,cardiovascular disease,and associated risk factors[J]. J Am Acad Dermatol,2013,69(6):1014-1024.

相似文献/References:

[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
　WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(9):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
　SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(9):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
　CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(9):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
　CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(9):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[5]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
　WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(9):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[6]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
　ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
　WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(9):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[8]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
　HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(9):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[9]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
　LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[10]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
　XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(9):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]

更新日期/Last Update: 2024-10-17